Navigating Complexity > Steering Decisions > Building Solutions Business Insights and Analytics Strategic and Scientific Consulting Scientific and Creative Communications Why we do what we do The healthcare industry is going through fundamental change and in this uncertainty our clients need to convert great science into winning strategy Our clients tell us they need our support in making the right strategic decisions that ensure their products fulfill their potential and ultimately improve people’s lives We love working at the cutting edge, helping to tackle our clients’ newest and most complex problems Teams of experts We are expert navigators helping guide our clients to more successful outcomes With a global perspective We work with 24 of the top 25 pharmaceutical companies as well as 100s of biotechs globally from our offices in the US and Europe Solving unique problems Whether we are supporting you on your journey, or delivering specialist expertise, we are helping you make important choices Share our fresh thinking > TCR T-cell Therapies: What if Magic Bullets Simply Aren't Good Enough? On the heels of a recent post in which I discussed evolving dynamics and strategic implications underscoring different types of allogeneic cell therapies in oncology, I find it fitting to address another substantive consideration in the field, that of targeting moieties. Donor-derived T-cells vs. iPSC- and Cord-derived NKs: Allo Not Created Equal A common question I get from my cancer cell therapy clients at Cello Health BioConsulting is why, despite the lion share of clinical data in support of T-cell therapies, it is NK cell therapy candidates (iPSC- and cord-derived) that seem of late to be capturing so much more enthusiasm from investors and Pharma these days?The answer has to do in large part with the risk-averse nature of Pharma, which in this case has been laudable. Different perspectives on the Burden of Disease What do medical market research and health economic outcomes research have in common? How can we combine our work on burden of disease in a way which realises it fullest potential? What can we learn from each other’s approach?Our starting pointAs we became acquainted with the work of our colleagues in the Health Economic Outcomes research world, we came to realise that we overlapped in areas of research with patients, but that in other fundamental ways we were differing – for example in our. Let’s work together The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today. Keep in touch @cellohealth /cello-health /cello-health-talent @hello_cello_us Contact us Privacy policy Covid-19 Commitment Modern Slavery Statement Cookie Control Icon